Overview

Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The aim of this study is to compare the clinical effectiveness of intravenous esomeprazole and pantoprazole in preventing recurrent bleeding in the patients with high-risk bleeding peptic ulcers after successful standard endoscopic hemostasis.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Lotung Poh-Ai Hospital
Collaborator:
Tomorrow Medical Foundation
Treatments:
Esomeprazole
Pantoprazole
Criteria
Inclusion Criteria:

- aged more than 18 years

- undergo emergent endoscopy within 24 hours of presentation

- have peptic ulcers in the gastroesophageal junction, stomach, or duodenum

- high-risk stigmata of peptic ulcers: Forrest classification IA~IIB

- endoscopic hemostasis by thermocoagulation or clip placement

Exclusion Criteria:

- pregnant or lactating

- written informed consent not obtained

- initial endoscopic hemostasis fail

- bleeding tendency (platelet count < 50×109/L, prolonged prothrombin time for more than
3 seconds, or were taking anticoagulants)

- PPI use within 14 days of enrollment

- comorbid with severe hepatic or renal insufficiency (serum total bilirubin more than 5
mg/dL, serum creatinine more than 5 mg/dL, or under dialysis)

- bleeding gastric cancers